ARS Pharmaceuticals faces class action after SPRY shares fall 23.9%
AI Summary- ARS Pharmaceuticals shareholders filed a securities class action over statements about neffy coverage and CVS Caremark.
- SPRY shares fell $2.52, or 23.9%, from $10.54 to $8.02.
- The class period covers purchases from March 9 through June 24, 2026.